A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors
收藏DataCite Commons2025-10-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011851/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to characterize the effect of repeat-dose administration of brigatinib 180 milligram (mg) once daily (QD) on the single-dose pharmacokinetics (PK) of midazolam.
提供机构：
Vivli
创建时间：
2025-10-09
